ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,262.73
-0.28%
Dow Jones
38,436.83
-0.64%
US Dollar vs MXN
17.70925
4.23%
Brent Oil
78.365
-3.02%
Bitcoin
69,353.63
2.37%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
Símbolo desconocido
Fecha:
Ordernar por:
FechaHoraFuenteTítuloSímboloCompañía
03/06/202413:30GlobeNewswire Inc.Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual MeetingTG:2GHMerus NV
03/06/202413:30GlobeNewswire Inc.MCLA-129 von Merus zeigt in Posterpräsentation auf der ASCO®-Jahrestagung 2024 eine vielversprechende Wirksamkeit als Einzelwirkstoff bei METex14-NSCLCTG:2GHMerus NV
03/06/202413:30GlobeNewswire Inc.L’anticorps MCLA-129 produit par Merus ou la promesse d’une monothérapie efficace dans le traitement du CPNPC présentant une mutation de l’exon 14 du gène MET - une présentation sous forme de poster est prévue lors du congrès annuel 2024 deTG:2GHMerus NV
03/06/202413:30Business WireMythic Therapeutics Presents Initial Dose Escalation Data from Ongoing Phase 1 KisMET-01 Study on MYTX-011 at the American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/202413:30PR Newswire (US)Itaipu ends participation in the 10th World Water Forum
03/06/202413:30PR Newswire (US)Late-breaking results from PALOMA-2 study of subcutaneous amivantamab in combination with lazertinib show clinically meaningful antitumor response and improved safety profile in patients with EGFR-mutated non-small cell lung cancer
03/06/202413:30PR Newswire (US)BRIXTON appoints Brian White, Industry Veteran, as SVP of US Wholesale
03/06/202413:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:WENWendys Company
03/06/202413:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:LEGLeggett and Platt Inc
03/06/202413:29PR Newswire (US)Royce Small-Cap Trust, Inc. (formerly Royce Value Trust, Inc.) (NYSE-RVT) declares Second Quarter Common Stock Distribution of $0.28 Per ShareNYSE:RVTRoyce Small Cap Trust Inc
03/06/202413:29PR Newswire (Canada)Thalia Chooses Coveo to Deliver AI-Powered Search, Recommendations and Personalization to Book EnthusiastsTSX:CVOCoveo Solutions Inc
03/06/202413:28Edgar (US Regulatory)Form 424B2 - Prospectus [Rule 424(b)(2)]NYSE:VZVerizon Communications Inc
03/06/202413:28Business WireXylem skaliert Nachhaltigkeit mit neuen Zielen für das WassermanagementNYSE:XYLXylem Inc
03/06/202413:27GlobeNewswire Inc.Pixalate Unveils the Global Web Publisher Trust Index: New Monthly Rankings Revealing the Top 100 Websites for Open Programmatic Ad Traffic Quality Across 235+ Countries, 4 Regions & 20+ IAB Categories
03/06/202413:27Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NYSE:NRUCNational Rural Utilities Cooperative Finance Corporation
03/06/202413:27Edgar (US Regulatory)Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]USOTC:PCCYFPetrochina Co Ltd (PK)
03/06/202413:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]USOTC:JMTMJames Maritime Holdings Inc (PK)
03/06/202413:27PR Newswire (US)New and Certified Vehicle Movement Hit Three Year Highs
03/06/202413:26GlobeNewswire Inc.Tower Federal Credit Union Earns Great Place to Work® Certification—Six Years in a Row!
03/06/202413:26PR Newswire (US)VIRTUOSO® BRINGS ITS 2024 SYMPOSIUM TO DUBAI, ENGAGING OVER 400 TOP TRAVEL EXECUTIVES
03/06/202413:23PR Newswire (US)Jo Malone London hosts grand opening event for new flagship store in Tokyo
03/06/202413:22PR Newswire (US)CHICAGO SPORTS NETWORK (CHSN) TO LAUNCH AS NEW HOME TO THE CHICAGO BLACKHAWKS, BULLS AND WHITE SOX
03/06/202413:21Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:POWLPowell Industries Inc
03/06/202413:20Edgar (US Regulatory)Form 8-K - Current reportAMEX:FOXOFOXO Technologies Inc
03/06/202413:19PR Newswire (Canada)Les cols blancs de Sainte-Marthe-sur-le-Lac en grève !
03/06/202413:18PR Newswire (US)New Study Reveals Key Brain Differences in Depression
03/06/202413:17PR Newswire (US)YA Group Acquires Bloomberg Consulting, Expands National Accident Reconstruction and Biomechanical Services
03/06/202413:16Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesUSOTC:TNTTFToronto Dominion Bank (PK)
03/06/202413:16PR Newswire (Canada)RF CAPITAL REPORTS AUA OF $37.1 BILLION FOR MAY 2024TSX:RCGRF Capital Group Inc
03/06/202413:15Business WireReal-World Research Presented at ASCO 2024 Indicates Clinical Trial Participation by Older Adults with Cancer Does Not Affect Emergency Room Visits or Hospice Enrollment

Su Consulta Reciente

ASX
EDU
EDU
NYSE
KBH
KB Home
LSE
0QET
Alliance Developpement C...
LSE
0KJ0
Sumol+compal
LSE
DPP
Dp Poland
NASDAQ
SUMO
Sumo Logic
ASX
AHK
ARK Mines
NASDAQ
BCG
Binah Capital
LSE
0KF1
Questerre Energy
LSE
CFYN
Caffyns
ASX
AO3HB
Apollo Series 2018 1
ASX
EM2
Eagle Mountain Mining
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados